Dr. Pravina Koteshwar is a health care professional, she brings over twenty-two (22+) plus years of rich experience of clinical research and therapeutics.

She started her career as Medical Advisor & HOD of Pharmacology & Toxicology, R&D Centre, Natural Remedies Pvt. Ltd., Bangalore. She was actively involved in planning & product development in accordance to national and international specifications. The key responsibilities included strategic planning, budgeting, execution & supervision of clinical projects related to allergy & immunology, neurology and metabolic disorders.

She contributed to the intensification of clinical research training at Institute of Clinical Research, (India), Bangalore. During her tenure as Assistant Dean & Principal at ICRI, creatively contributed to designing and developing various courses (Master's and Diploma programs) and training modules in clinical research and related fields as per the industry needs and specifications.

As the Course Director, India, for M.Sc. Clinical Research of Cranfield University, UK, she was responsible for consistency and quality education of international standards to be delivered at all campuses of ICRI in India. She has achieved Recognized Teacher Status (RTS) by Cranfield, UK, an eligibility criteria for teaching and guiding postgraduate students.

She established research consultancy services to various organizations including Sponsors and CROs. She has played multiple roles as medical advisor, clinical monitor, project manager, investigator and co- investigator, research guide, etc. in different clinical settings. She has an expertise in critical review and scientific analysis of research dossiers, study protocols and reports.

She is very passionate about ethical aspects of clinical research. She was the Founder and member secretary of ICRI Independent Ethics committee – Bangalore (IIECB). Presently, she is the Member Secretary of Sri Sri Institutional Ethical Committee (SSIEC), Bangalore.

She is heading the department of emergency medical services at Sri Sri College of Ayurvedic Science Hospital & Research Centre, Bangalore. She is a consultant physician in the diabetic management and palliative cancer care. Actively involved in training the undergraduate, postgraduate students and nonclinical staff of hospital on Basic Life Support and emergency medical care. She is trained in Hyperbaric Oxygen Therapy (HBOT).

By qualification Dr Pravina holds MD in clinical pharmacology from Karnataka Institute of Medical Sciences, Hubli, Karnataka in 2002.

Dr Pravina lives at Bangalore and she is contributing to society by organizing and conducting many healthcare activities such as health camps, school health activities, health education and awareness programs for general public, students and employees in different organizations both at urban and rural areas of Bangalore.

Guru P. Sonpavde, MD is the Director of Genitourinary (GU) Oncology and Phase I Research as well as the Christopher K. Glanz Chair for Bladder Cancer Research at the AdventHealth Cancer Institute, Orlando, Florida. Additionally, he holds a position of Professor of Medicine at the University of Central Florida. Previously, he was Bladder Cancer Director at the Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School from 2017-2022, GU Oncology Director and Associate Professor of Medicine at the University of Alabama at Birmingham from 2012 to 2017 and practiced from 2004 to 2012 at Texas Oncology, a US Oncology affiliate. His focus is drug development (including early development Phase I clinical trials and later Phase II/III trials) evaluating immunotherapy, targeted therapy, antibody-drug-conjugates and other novel and emerging classes of treatments (e.g., Bi-Specific T-cell engagers, CAR-T cells) across solid tumors and clinical/translational research to cure GU cancers with a focus on bladder cancer. He serves on the steering committees of several pivotal phase III trials evaluating treatments for bladder cancer. Under his leadership, the Phase I and GU Oncology programs have grown robustly at the AdventHealth Cancer Institute. His research efforts have led to ~500 publications. He also enjoys interacting with medical residents and fellows in order to teach and mentor research projects leading to presentations and publications. He is a member of Southwest Oncology Group, Scientific Advisory Board of the Bladder Cancer Advocacy Network (BCAN), and the Bladder Cancer Task Force of U.S. NCI GU Steering Committee. He has often contributed to or has been cited in video and written cancer education portals including Uptodate®, Practice Update, Onclive, Physician Education Resource (PER), and Research to Practice. He has also been cited in several lay magazine articles notably in TIME magazine regarding participation in clinical trials in August 2022: https://time.com/6210644/bladder-cancer-clinical-trials/

Dr. Geetu Bhandoria is a Healthcare practitioner with 20+ years of experience, An Obstetrician & Gynaecologist since 2009, and a Gyna-Oncologist since 2017. Dr Bhandoria's academic interests encompass the exploration of the academic potential of social media, particularly in the field of Oncology, as well as the study of Enhanced Recovery Pathways, Peritoneal Surface Oncology, and Advanced Ovarian Cancer. A keen researcher and creating a global Gynaecologic Oncology community.
Possess additional expertise in Healthcare Leadership and providing guidance to aspiring individuals.

Dr Bhandoria is associated with various international scientific societies, including the International Gynaecological Cancer Society (IGCS), the Early Career Network of IGCS, the Research & Publications Network, and the International Gynaecological Cancer Advocacy Network (IGCAN).
Dr. Bhandoria also holds the position of a recognized postgraduate teacher for Obstetrics and gynaecology at the university.

Dr. Bhandoria’s professional background encompasses a range of roles, including serving as a Consultant in Gynaecologic Oncology and obstetrics at Command Hospital in both Kolkata (since 2020) and Pune (2017-2020). Additionally, He has held positions as a Faculty member for the Early Career, Networking & Publications Network at the International Gynaecologic Cancer Society (IGCS), a member of the Early-career Editorial Board for the International Journal of Gynaecologic Cancer (IJGC), a Committee member for the international Gynaecological Cancer Advocacy Network (IGCAN), an Executive member for The Association of Gyn Oncologists of India (AGOI), and a member of the Healthcare Leadership Academy (HLA).

Dr Bhandoria has also completed several fellowships, including Gynecologic Oncology at The Gujarat Cancer & Research Institute, an Editorial fellowship at IJGC, European Society of Gynecologic Oncology Travel fellowship, Union for International Cancer Network Technical fellowship, and Medics Academy fellowship.

Professor Bertil E. Lindmark Professor Bertil E. Lindmark is a Healthcare practitioner with 35+ years of experience. Dr. Bertil possesses extensive knowledge in leading and managing scientific innovation, smart drug development, effective derisking, balancing investment portfolios, ensuring market access, drug defence, and commercial optimization.

Dr. Bertil is currently associated as the Chief Medical Officer (CMO) at Galecto, located in the center of Copenhagen. Additionally, Dr. Bertil also holds the position of Chairman of the Board at AQILION AB, Sweden.

Dr. Bertil holds a position on the Board of Directors at Cellevate AB, a Swedish-based company.

Dr. Bertil was the former Chief Medical Officer at eTheRNA Immunotherapies in Belgium, developing therapeutic vaccines and local in situ immunomodulators for oncology. He acquired valuable expertise in the realm of immunoregulation and vaccine technology through his professional endeavors.

Dr. Bertil has dedicated over four years of his expertise to ASLAN Pharmaceuticals, serving as their Chief Medical Officer (CMO) and Chief Scientific Officer (CSO), where he developed three compounds and performed two IPOs.

Dr. Bertil served as a VP and Head Clinical Division in AstraZeneca Japan R&D and also contributed as a Global Therapy Area Clinical VP RITA where he expanded the AstraZeneca respiratory portfolio by leading the clinical development of early- and late-stage products.

In addition, Dr. Bertil was also appointed as a Global Therapy Area Medical Director and Director Medical Science at AstraZeneca, where he oversaw the company’s Respiratory and Inflammation (R&I) therapy research division as the medical expert and strategic lead.

Dr. Bertil also served as the Director of Drug Safety and Epidemiology at AstraDraco for a span of 9 years.

Over the course of a decade of clinical medicine, he has learned the importance of meticulous evaluation and utilizing comprehensive information to arrive at an accurate diagnosis. This serves as the fundamental cornerstone for effective treatment while also fostering a profound understanding and compassion for individuals enduring illness.